Notably, the correlative immune analysis showed that Hsp90 inhibition changed the tumor immune profile, with decreases in IL-6-producing cells and tumor-associated macrophages and system-wide increases in inflammatory cytokines, which implies enhanced immune activation. Here, HSP90AB1 is linked to neoplasm.